Você esta aqui:Home > Therapeutics (antigo) > Cannabis in Multiple Sclerosis: Women’s Health Concerns

J Cannabis Ther 2002(3/4):159-173

Multiple Sclerosis

Cannabis in Multiple Sclerosis: Women’s Health Concerns

Author
DJ. Petro

Abstract
Women's health has received greater attention with the recognition of significant differences in disease expression and drug action in men and women. Multiple sclerosis is a neurological disorder with important gender differences. MS patients have employed cannabis to treat a number of symptoms associated with the disease including spasticity, pain, tremor, fatigue, and autonomic dysfunction. The scientific literature includes supportive case reports, single-patient (N-of-1) trials and randomized clinical trials. Large-scale clinical trials are underway to answer questions concerning the efficacy and safety of cannabis in patients with MS. While these studies will answer important questions concerning the actions of cannabinoids on the nervous system, additional studies in female MS patients will be needed to address issues such as gender-specific actions on symptoms such as pain and autonomic dysfunction along with studies in menopausal and post-menopausal women. Since the drug-drug interactions have been reported with cannabinoids, the effects of cannabis on the actions of other centrally-acting drugs should be explored.

Keywords
Women's health has received greater attention with the recognition of significant differences in disease expression and drug action in men and women. Multiple sclerosis is a neurological disorder with important gender differences. MS patients have employed cannabis to treat a number of symptoms associated with the disease including spasticity, pain, tremor, fatigue, and autonomic dysfunction. The scientific literature includes supportive case reports, single-patient (N-of-1) trials and randomized clinical trials. Large-scale clinical trials are underway to answer questions concerning the efficacy and safety of cannabis in patients with MS. While these studies will answer important questions concerning the actions of cannabinoids on the nervous system, additional studies in female MS patients will be needed to address issues such as gender-specific actions on symptoms such as pain and autonomic dysfunction along with studies in menopausal and post-menopausal women. Since the drug-drug interactions have been reported with cannabinoids, the effects of cannabis on the actions of other centrally-acting drugs should be explored.

PDF do texto completo ]

Free Online Events 2020

You can find all information here.

The IACM is holding a free webinar series and a free anniversary online meeting from October to November 2020

All webinars will be held in English with subtitles in German, French, Spanish, and Portuguese. All webinars will be available online until March 2021

The anniversary online meeting to celebrate the IACM's 20th anniversary and to honour the 90th birthday of Raphael Mechoulam will be a live session only on the 5th November 2020.

The speakers in the webinar series are Donald I. Abrams, Bonni Goldstein, Franjo Grotenhermen, Manuel Guzmán, Raphael Mechoulam, Kirsten Müller-Vahl, Roger Pertwee, Daniele Piomelli, and Ethan Russo.

You can find all information here.

Conferência 2021

A 12ª Conferência da IACM sobre Canabinoides em Medicina será realizada em Basileia, Suíça, de 14 a 16 de Outubro de 2021.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.